ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jan 2019
Last Updated on 03 Jun 2024
A- A+
Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C Guidance and PES is outdated and has been withdrawn on 3 June 2024. PES Direct-acting antiviral agents for treating chronic hepatitis C (Withdrawn 3 Jun 24) Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C (Withdrawn 3 Jun 24)